Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive save search
Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting
Published: 2024-03-22 (Crawled : 12:00) - prnewswire.com
ALPMF | News | $9.5 1.2K
|
Health Technology
|
| O: -0.54%
H: 0.0%
C: 0.0%
ALPMY | News | $9.47 400K
|
Manufacturing
|
| O: 2.26%
H: 0.0%
C: -2.65%
chmp positive cancer treatment
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
Published: 2024-03-22 (Crawled : 12:00) - globenewswire.com
OTLK | News P | $8.2 0.0% 19
|
Health Technology
|
| O: 52.98%
H: 8.82%
C: -19.87%
ons-5010 therapeutics chmp positive treatment
Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
Published: 2024-03-22 (Crawled : 12:00) - globenewswire.com
NVS | News | $98.67 0.33% 260K
|
Health Technology
|
| O: 0.17%
H: 0.28%
C: -0.01%
fabhalta first chmp positive novartis
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
Published: 2024-03-21 (Crawled : 20:00) - biospace.com/
LUCD | $0.661 -3.24% 32K
|
|
| O: -0.9%
H: 8.18%
C: 0.91%
PAVM | $1.85 -1.07% -3.89% 1
|
Health Technology
|
| O: 0.45%
H: 5.41%
C: -4.5%
esoguard first positive diagnostics study
LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea
Published: 2024-03-20 (Crawled : 19:00) - biospace.com/
LIVN | $54.52 -2.54% 27K
|
Health Technology
|
| O: 1.81%
H: 11.57%
C: 10.5%
success positive trial study
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
Published: 2024-03-20 (Crawled : 12:00) - globenewswire.com
FEMY | $1.33 5.2K
|
Manufacturing
|
| O: -6.5%
H: 0.53%
C: -3.74%
femaseed positive treatment topline trial
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
Published: 2024-03-20 (Crawled : 11:00) - globenewswire.com
SLRN | $4.57 -0.65% -0.66% 0
|
|
| O: 2.39%
H: 5.4%
C: 2.09%
first disease positive thyroid eye
Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ
Published: 2024-03-19 (Crawled : 15:30) - biospace.com/
HOTH | $1.17 220
|
Health Technology
|
| O: 21.74%
H: 19.29%
C: -3.57%
disease pre-clinical positive treatment alzheimer's therapeutics ht-alz study
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients
Published: 2024-03-19 (Crawled : 15:00) - biospace.com/
CERS | $1.66 22K
|
Health Technology
|
| O: 12.9%
H: 5.71%
C: -2.86%
corporation positive blood system topline trial cardiovascular results
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
Published: 2024-03-19 (Crawled : 13:30) - biospace.com/
MRK | $131.065 3.2% 2.5M
|
Health Technology
|
| O: 0.0%
H: 0.68%
C: 0.63%
pneumococcal vaccine merck positive
IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy
Published: 2024-03-19 (Crawled : 12:30) - prnewswire.com
ICCM | $1.22 12K
|
Manufacturing
|
| O: 2.07%
H: 0.0%
C: 0.0%
free company breast one positive cancer women topline medical alternative results
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
Published: 2024-03-18 (Crawled : 20:00) - globenewswire.com
IVA | $3.24 -1.52% -0.3% 0
|
Health Technology
|
| O: -9.4%
H: 0.0%
C: -12.66%
positive results study
High Tide Reports First Quarter 2024 Financial Results Featuring Record Revenue, Record Adjusted EBITDA, and Third Consecutive Quarter of Positive Free Cash Flow as well as Break-Even Net Income
Published: 2024-03-15 (Crawled : 20:00) - hightideinc.com
HITI | $1.985 -1.73% 53K
|
Manufacturing
| Email alert
Add to watchlist
first free positive flow financial results
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
Published: 2024-03-15 (Crawled : 12:30) - globenewswire.com
FBIO | $1.79 -1.11% -1.4% 0
|
Health Technology
|
| O: 2.98%
H: 15.03%
C: 11.85%
ATXI | $0.088 -6.68% 1.3M
|
Health Technology
|
| O: -0.26%
H: 13.2%
C: 1.88%
nasdaq positive therapeutics
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia
Published: 2024-03-15 (Crawled : 12:00) - globenewswire.com
JSPR | $21.17 -3.9% 3.1K
|
|
| O: -0.41%
H: 5.52%
C: 3.42%
anemia positive
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
Published: 2024-03-14 (Crawled : 12:30) - biospace.com/
CYBN | $0.348 -1.97% 210K
|
n/a
|
| O: 7.14%
H: 5.53%
C: -4.67%
cyb003 fda positive meeting program design
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
Published: 2024-03-14 (Crawled : 11:00) - globenewswire.com
IMRX | $1.5 50K
|
|
| O: -21.09%
H: 7.96%
C: -37.5%
tumors positive topline trial results
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
Published: 2024-03-13 (Crawled : 15:00) - biospace.com/
SLN | $22.27 -1.07% -0.81% 0
|
Health Technology
|
| O: -5.02%
H: 5.71%
C: 4.11%
positive ongoing topline therapeutics study
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
Published: 2024-03-13 (Crawled : 13:30) - biospace.com/
TAK | News | $13.23 -1.12% 0.23% 690
|
Health Technology
|
| O: 0.21%
H: 0.17%
C: 0.14%
tak-079 positive topline potential results study
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
Published: 2024-03-13 (Crawled : 11:00) - prnewswire.com
IONS | $42.195 -0.6% 99K
|
Health Technology
|
| O: 0.69%
H: 1.1%
C: -0.71%
ion224 positive treatment results study
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
CSSE 4 | $0.299 96.32% 7M
|
Consumer Services
BRFH 4 | $1.99 80.91% 13M
|
Manufacturing
LICN | $1.0 78.57% 3.3M
|
BOF | $1.915 63.68% 620K
|
MTC | $3.62 61.61% 790K
|
Technology Services
AMST | $3.13 56.5% 500K
|
Technology Services
ACON | $0.3595 24.83% 3.5M
|
n/a
ILAG | $0.669 23.89% 13M
|
CDTX | News | $14.57 18.55% 330K
|
Health Technology
MNY | $2.11 17.22% 180K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.